Frontlight ResearchEarly access
WithdrawnPhase 4
Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 16 Apr 2024
- Expected to end
- Jan 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Methylphenidate
- Placebo
- Record updated
- 15 March 2024
- Why it stopped
- Study withdrawn in IRB by PI
Who can take part
- Age
- 6 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 6 to 18 years
- Diagnosis of ADHD
- A score of at least 3 (mildly ill) on the clinician administered Clinical Global Impressions-Severity (CGI-S)
Who cannot take part
- Currently taking stimulant medications (within one week of first study visit). Patients will not be asked to discontinue any treatments for the purpose of this research study. Subjects will include treatment naïve patients and patients who were previously treated with stimulant medications, but are not currently treated, and meet study criteria
- Having an adverse reaction to methylphenidate, or other stimulant medication
- Having a contraindication to MRI, including a pacemaker, defibrillator or other medical implant, other metal objects, or claustrophobia, or for having braces or other metal in the head region (likely to create an artifact on the MRI scans)
- Current psychiatric disorder, including bipolar I or II disorder, major depressive, disorder, obsessive-compulsive disorder, autism spectrum disorder, Tourette syndrome, or history of psychosis
- Confirmed genetic disorder with cognitive and/or behavioral disturbances
- Active, unstable medical illness that may interfere with cognition or compromises safety of the patient
- History of head trauma with loss of consciousness or any evidence of functional impairment due to, and persisting after, head trauma
- Neurological disorder, mental retardation, intellectual or disability, or other non-ADHD cause of cognitive impairment
- Patient is at risk for clinically significant deterioration due to study protocol, as assessed by primary medical investigator (Dr. Grant)
- Pregnant or breast-feeding women
- Currently smoking or using controlled or illicit substances, including alcohol
Where in United States
- Johns Hopkins School of MedicineBaltimore, United States
About the trial
What the trial wants to find out
The goal of this proposal is to develop brain imaging tools to measure the effects of methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD). Methylphenidate is an FDA-approved treatment for ADHD. Specifically, the investigators will correlate brain activity during cognitive tasks and brain chemistry with cognitive performance. These measures could help the investigators understand how current ADHD medications work and then could be used to develop novel drugs to treat ADHD in children and adolescents.
The 3 groups in the trial
- Methylphenidate - low doseTreatment being tested
5 mg of methylphenidate
Treatment: Methylphenidate
- Methylphenidate - high doseTreatment being tested
10 mg of methylphenidate
Treatment: Methylphenidate
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Children and Adolescents With ADHD
- Record updated
- 15 March 2024